Suppr超能文献

肾细胞癌的分期:当前概念

Staging of renal cell carcinoma: Current concepts.

作者信息

Lam John S, Klatte Tobias, Breda Alberto

机构信息

Roy and Patricia Disney Family Cancer Center, Providence Saint Joseph Medical Center, Burbank, CA 91505, USA.

出版信息

Indian J Urol. 2009 Oct-Dec;25(4):446-54. doi: 10.4103/0970-1591.57906.

Abstract

The most important and widely utilized system for providing prognostic information following surgical management for renal cell carcinoma (RCC) is currently the tumor, nodes, and metastasis (TNM) staging system. An accurate and clinically useful staging system is an essential tool used to provide patients with counseling regarding prognosis, select treatment modalities, and determining eligibility for clinical trials. Data published over the last few years has led to significant controversies as to whether further revisions are needed and whether improvements can be made with the introduction of new, more accurate predictive prognostic factors. Staging systems have also evolved with an increase in the understanding of RCC tumor biology. Molecular tumor biomarkers are expected to revolutionize the staging of RCC by providing more effective prognostic ability over traditional clinical variables alone. This review will examine the components of the TNM staging system, current staging modalities including comprehensive integrated staging systems, and predictive nomograms, and introduce the concept of molecular staging for RCC.

摘要

目前,用于提供肾细胞癌(RCC)手术治疗后预后信息的最重要且应用最广泛的系统是肿瘤、淋巴结和转移(TNM)分期系统。准确且临床实用的分期系统是用于为患者提供预后咨询、选择治疗方式以及确定临床试验资格的重要工具。过去几年发表的数据引发了关于是否需要进一步修订以及引入新的、更准确的预测预后因素是否能带来改善的重大争议。随着对RCC肿瘤生物学认识的增加,分期系统也在不断演变。分子肿瘤生物标志物有望通过单独提供比传统临床变量更有效的预后能力,彻底改变RCC的分期。本综述将审视TNM分期系统的组成部分、当前的分期方式,包括综合集成分期系统和预测列线图,并介绍RCC分子分期的概念。

相似文献

1
Staging of renal cell carcinoma: Current concepts.
Indian J Urol. 2009 Oct-Dec;25(4):446-54. doi: 10.4103/0970-1591.57906.
2
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
J Urol. 2005 Jun;173(6):1853-62. doi: 10.1097/01.ju.0000165693.68449.c3.
3
Prognostic factors in renal cell carcinoma.
Semin Oncol. 2006 Oct;33(5):563-75. doi: 10.1053/j.seminoncol.2006.06.006.
4
Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma.
J Clin Oncol. 2006 Dec 10;24(35):5565-75. doi: 10.1200/JCO.2006.08.1794.
5
Prognostic factors and selection for clinical studies of patients with kidney cancer.
Crit Rev Oncol Hematol. 2008 Mar;65(3):235-62. doi: 10.1016/j.critrevonc.2007.08.003. Epub 2007 Oct 10.
6
Role of molecular markers in the diagnosis and therapy of renal cell carcinoma.
Urology. 2005 Nov;66(5 Suppl):1-9. doi: 10.1016/j.urology.2005.06.112.
7
Prognostic factors in renal cell carcinoma.
World J Urol. 2010 Jun;28(3):319-27. doi: 10.1007/s00345-010-0540-8. Epub 2010 Apr 3.
9
The staging of renal cell carcinoma.
Curr Opin Urol. 2008 Sep;18(5):455-61. doi: 10.1097/MOU.0b013e32830a4f36.
10
TNM staging system for renal-cell carcinoma: current status and future perspectives.
Lancet Oncol. 2007 Jun;8(6):554-8. doi: 10.1016/S1470-2045(07)70173-0.

引用本文的文献

1
iRECIST-based versus non-standardized free text reporting of CT scans for monitoring metastatic renal cell carcinoma: a retrospective comparison.
J Cancer Res Clin Oncol. 2022 Aug;148(8):2003-2012. doi: 10.1007/s00432-022-03997-0. Epub 2022 Apr 14.
2
MRI-Based Grading of Clear Cell Renal Cell Carcinoma Using a Machine Learning Classifier.
Front Oncol. 2021 Oct 1;11:708655. doi: 10.3389/fonc.2021.708655. eCollection 2021.
4
Nucleobindin-2 enhances the epithelial-mesenchymal transition in renal cell carcinoma.
Oncol Lett. 2020 Jun;19(6):3653-3664. doi: 10.3892/ol.2020.11526. Epub 2020 Apr 10.
5
CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.
Oncol Rep. 2018 Oct;40(4):2023-2035. doi: 10.3892/or.2018.6590. Epub 2018 Jul 23.
6
Tumor thrombus: incidence, imaging, prognosis and treatment.
Cardiovasc Diagn Ther. 2017 Dec;7(Suppl 3):S165-S177. doi: 10.21037/cdt.2017.09.16.
7
Pathological upstaging of clinical T1 renal cell carcinoma: an analysis of 115,835 patients from National Cancer Data Base, 2004-2013.
Int Urol Nephrol. 2018 Feb;50(2):237-245. doi: 10.1007/s11255-017-1768-7. Epub 2017 Dec 15.
8
Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.
Oncotarget. 2016 Sep 20;7(38):62255-62266. doi: 10.18632/oncotarget.11555.
9
Correlation between BOLD-MRI and HIF expression level in renal carcinoma.
Int J Clin Exp Pathol. 2015 Oct 1;8(10):13759-63. eCollection 2015.

本文引用的文献

1
Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram.
BJU Int. 2008 Jan;101(1):39-43. doi: 10.1111/j.1464-410X.2007.07170.x. Epub 2007 Oct 1.
2
Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma.
J Urol. 2007 Nov;178(5):1878-82. doi: 10.1016/j.juro.2007.07.011. Epub 2007 Sep 17.
3
Prognostic factors for renal cell carcinoma with tumor thrombus extension.
J Urol. 2007 Oct;178(4 Pt 1):1189-95; discussion 1195. doi: 10.1016/j.juro.2007.05.134. Epub 2007 Aug 14.
5
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience.
J Urol. 2007 Jul;178(1):35-40; discussion 40. doi: 10.1016/j.juro.2007.03.046. Epub 2007 May 22.
7
Multi-institutional validation of a new renal cancer-specific survival nomogram.
J Clin Oncol. 2007 Apr 10;25(11):1316-22. doi: 10.1200/JCO.2006.06.1218.
8
Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience.
Eur Urol. 2007 Jul;52(1):155-62. doi: 10.1016/j.eururo.2007.01.106. Epub 2007 Feb 7.
9
Cancer statistics, 2007.
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验